▶ 調査レポート

ジフテリア、破傷風、百日咳(DTaP)ワクチンの世界市場 2020年:メーカー別、地域別、種類・用途別

• 英文タイトル:Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。ジフテリア、破傷風、百日咳(DTaP)ワクチンの世界市場 2020年:メーカー別、地域別、種類・用途別 / Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / D005-05196資料のイメージです。• レポートコード:D005-05196
• 出版社/出版日:GlobalInfoResearch / 2020年5月22日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、104ページ
• 納品方法:Eメール
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、ジフテリア、破傷風、百日咳(DTaP)ワクチンの世界市場を広く調査・分析し、今後の市場展望をまとめております。ジフテリア、破傷風、百日咳(DTaP)ワクチンの種類別市場規模(免疫DTaPワクチン、治療DTaPワクチン)、用途別市場規模(成人、小児)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(販売量、市場シェア、製品概要、SWOT分析):Sanofi Pasteur、Pfizer Inc、Novartis AG、GlaxoSmithKline、Astellas Pharma US、Protein Sciences Corporation、Lanzhou Institute of Biological Products Co., Ltd、Merck Sharp & Dohme Corp、Seqirus、Johnson & Johnson、AstraZeneca、Emergent BioSolutions Inc
・地域別グローバル市場分析 2015年-2020年
・ジフテリア、破傷風、百日咳(DTaP)ワクチンの北米市場(アメリカ、カナダ、メキシコ)
・ジフテリア、破傷風、百日咳(DTaP)ワクチンのヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・ジフテリア、破傷風、百日咳(DTaP)ワクチンのアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・ジフテリア、破傷風、百日咳(DTaP)ワクチンの南米市場(ブラジル、アルゼンチン)
・ジフテリア、破傷風、百日咳(DTaP)ワクチンの中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:免疫DTaPワクチン、治療DTaPワクチン
・用途別分析:成人、小児
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market has been segmented into
Immune DTaP Vaccine
Therapy DTaP Vaccine

By Application, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine has been segmented into:
Adult
Pediatric

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market.

The report offers in-depth assessment of the growth and other aspects of the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Analysis
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, revenue and market share for each player covered in this report.

The major players covered in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine are:
Sanofi Pasteur
Pfizer Inc
Novartis AG
GlaxoSmithKline
Astellas Pharma US
Protein Sciences Corporation
Lanzhou Institute of Biological Products Co., Ltd
Merck Sharp & Dohme Corp
Seqirus
Johnson & Johnson
AstraZeneca
Emergent BioSolutions Inc

Among other players domestic and global, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with price, sales, revenue and global market share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2018 and 2019.
Chapter 3, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

Table of Contents

1 Market Overview
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Adult
1.3.3 Pediatric
1.4 Overview of Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi Pasteur SWOT Analysis
2.1.4 Sanofi Pasteur Product and Services
2.1.5 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer Inc
2.2.1 Pfizer Inc Details
2.2.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer Inc SWOT Analysis
2.2.4 Pfizer Inc Product and Services
2.2.5 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis AG SWOT Analysis
2.3.4 Novartis AG Product and Services
2.3.5 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Astellas Pharma US
2.5.1 Astellas Pharma US Details
2.5.2 Astellas Pharma US Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Astellas Pharma US SWOT Analysis
2.5.4 Astellas Pharma US Product and Services
2.5.5 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Protein Sciences Corporation
2.6.1 Protein Sciences Corporation Details
2.6.2 Protein Sciences Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Protein Sciences Corporation SWOT Analysis
2.6.4 Protein Sciences Corporation Product and Services
2.6.5 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Lanzhou Institute of Biological Products Co., Ltd
2.7.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.7.2 Lanzhou Institute of Biological Products Co., Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Lanzhou Institute of Biological Products Co., Ltd SWOT Analysis
2.7.4 Lanzhou Institute of Biological Products Co., Ltd Product and Services
2.7.5 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck Sharp & Dohme Corp
2.8.1 Merck Sharp & Dohme Corp Details
2.8.2 Merck Sharp & Dohme Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck Sharp & Dohme Corp SWOT Analysis
2.8.4 Merck Sharp & Dohme Corp Product and Services
2.8.5 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Seqirus
2.9.1 Seqirus Details
2.9.2 Seqirus Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Seqirus SWOT Analysis
2.9.4 Seqirus Product and Services
2.9.5 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Johnson & Johnson SWOT Analysis
2.10.4 Johnson & Johnson Product and Services
2.10.5 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 AstraZeneca SWOT Analysis
2.11.4 AstraZeneca Product and Services
2.11.5 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Emergent BioSolutions Inc SWOT Analysis
2.12.4 Emergent BioSolutions Inc Product and Services
2.12.5 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2019
3.3.2 Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Regions (2015-2020)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Regions (2015-2020)
4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
4.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
4.5 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Country
5.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Country (2015-2020)
5.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Country (2015-2020)
5.2 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
5.3 Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
5.4 Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Country
6.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Country (2015-2020)
6.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Country (2015-2020)
6.2 Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
6.3 UK Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
6.4 France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
6.5 Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
6.6 Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Regions (2015-2020)
7.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7.3 Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7.4 Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7.5 India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
7.7 Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Country
8.1.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Country (2015-2020)
8.1.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Country (2015-2020)
8.2 Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
8.3 Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
9.3 Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
9.4 Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
9.5 South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Market Share by Type (2015-2020)
10.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Type (2015-2020)
10.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2015-2020)
11 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Application
11.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2015-2020)
11.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2015-2020)
11.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2015-2020)
12 Market Forecast
12.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Growth Rate (2021-2025)
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast by Regions (2021-2025)
12.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025)
12.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025)
12.2.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025)
12.2.4 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025)
12.2.5 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025)
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast by Type (2021-2025)
12.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Type (2021-2025)
12.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Type (2021-2025)
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast by Application (2021-2025)
12.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Application (2021-2025)
12.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables

Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 9. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 10. Sanofi Pasteur SWOT Analysis
Table 11. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 12. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 15. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 16. Pfizer Inc SWOT Analysis
Table 17. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 18. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 20. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 21. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 22. Novartis AG SWOT Analysis
Table 23. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 24. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 26. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 27. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 28. GlaxoSmithKline SWOT Analysis
Table 29. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 30. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Astellas Pharma US Basic Information, Manufacturing Base and Competitors
Table 32. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 33. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 34. Astellas Pharma US SWOT Analysis
Table 35. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 36. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Protein Sciences Corporation Basic Information, Manufacturing Base and Competitors
Table 38. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 39. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 40. Protein Sciences Corporation SWOT Analysis
Table 41. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 42. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 44. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 45. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 46. Lanzhou Institute of Biological Products Co., Ltd SWOT Analysis
Table 47. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 48. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 50. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 51. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 52. Merck Sharp & Dohme Corp SWOT Analysis
Table 53. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 54. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Seqirus Basic Information, Manufacturing Base and Competitors
Table 56. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 57. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 58. Seqirus SWOT Analysis
Table 59. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 60. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 62. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 63. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 64. Johnson & Johnson SWOT Analysis
Table 65. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 66. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 68. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 69. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 70. AstraZeneca SWOT Analysis
Table 71. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 72. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Emergent BioSolutions Inc Basic Information, Manufacturing Base and Competitors
Table 74. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Business
Table 75. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Revenue (USD Million) (2017-2018)
Table 76. Emergent BioSolutions Inc SWOT Analysis
Table 77. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
Table 78. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturer (2018-2019) (K Doses)
Table 80. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2018-2019) (USD Million)
Table 81. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Regions (2015-2020) (K Doses)
Table 82. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Regions (2015-2020)
Table 83. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Regions (2015-2020) (USD Million)
Table 84. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Countries (2015-2020) (K Doses)
Table 85. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries (2015-2020)
Table 86. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 87. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020)
Table 88. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Countries (2015-2020) (K Doses)
Table 89. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries (2015-2020)
Table 90. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 91. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Regions (2015-2020) (K Doses)
Table 92. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Regions (2015-2020)
Table 93. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Regions (2015-2020) (USD Million)
Table 94. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Countries (2015-2020) (K Doses)
Table 95. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries (2015-2020)
Table 96. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 97. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020)
Table 98. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Countries (2015-2020) (K Doses)
Table 99. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries (2015-2020)
Table 100. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 101. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020)
Table 102. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2015-2020) (K Doses)
Table 103. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2015-2020)
Table 104. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2015-2020) (USD Million)
Table 105. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2015-2020)
Table 106. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2015-2020) (K Doses)
Table 107. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2015-2020)
Table 108. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Regions (2021-2025) (K Doses)
Table 109. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Regions (2021-2025)
Table 110. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Type (2021-2025) (K Doses)
Table 111. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Type (2021-2025)
Table 112. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Application (2021-2025)
Table 113. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Application (2021-2025)
Table 114. Direct Channel Pros & Cons
Table 115. Indirect Channel Pros & Cons
Table 116. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Picture
Figure 2. Global Sales Market Share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type in 2019
Figure 3. Immune DTaP Vaccine Picture
Figure 4. Therapy DTaP Vaccine Picture
Figure 5. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application in 2018
Figure 6. Adult Picture
Figure 7. Pediatric Picture
Figure 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Status and Outlook (2015-2025) (USD Million)
Figure 9. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 10. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 13. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 14. UK Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 17. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 20. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 23. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 26. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturer in 2019
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturer in 2019
Figure 30. Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2019
Figure 31. Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer (Revenue) Market Share in 2019
Figure 32. Key Manufacturer Market Share Trend
Figure 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Regions (2015-2020)
Figure 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Regions in 2018
Figure 37. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
Figure 38. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
Figure 40. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
Figure 41. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020)
Figure 42. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 43. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries (2015-2020)
Figure 44. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries in 2018
Figure 45. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 46. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries in 2018
Figure 47. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 48. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 49. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 50. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 51. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 52. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries in 2019
Figure 53. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 54. UK Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 55. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 56. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 57. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 58. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 59. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Regions 2019
Figure 60. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Regions 2019
Figure 61. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 62. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 63. Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 64. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 65. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 66. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 67. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries in 2019
Figure 68. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries in 2019
Figure 69. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 70. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 71. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Countries in 2019
Figure 73. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 74. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Countries in 2019
Figure 75. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 76. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 77. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 78. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2015-2020) (K Doses)
Figure 79. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Growth Rate (2021-2025) (K Doses)
Figure 80. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Growth Rate (2021-2025) (USD Million)
Figure 81. North America Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025) (K Doses)
Figure 82. Europe Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025) (K Doses)
Figure 83. Asia-Pacific Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025) (K Doses)
Figure 84. South America Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025) (K Doses)
Figure 85. Middle East & Africa Sales Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Forecast (2021-2025) (K Doses)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel